NASDAQ:CERS

Cerus (CERS) Stock Price, News & Analysis

Cerus logo
$2.00 +0.11 (+5.53%)
As of 01:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Cerus Stock (NASDAQ:CERS)

Advanced

Key Stats

Today's Range
$1.88
▼
$2.09
50-Day Range
$1.86
▼
$2.67
52-Week Range
$1.47
▼
$3.47
Volume
2.45 million shs
Average Volume
2.17 million shs
Market Capitalization
$404.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25
Consensus Rating
Hold

Company Overview

Cerus Corporation is a biomedical products company focused on improving the safety of blood components used for transfusions. Its primary offering is the INTERCEPT Blood System, which uses a pathogen-reduction process designed to inactivate a broad range of viruses, bacteria, parasites and white blood cells in donated blood components.

INTERCEPT is used to process platelet and plasma components. Cerus also develops related processing devices and supplies for blood centers and transfusion services. The company’s work has centered on reducing the risk of transfusion-transmitted infections and supporting the availability of treated blood products.

Founded in 1991, Cerus serves blood centers and healthcare organizations in the United States and international markets. Its products are subject to regulatory approvals and availability can vary by geography.

AI Generated. May Contain Errors.

Cerus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

CERS MarketRank™: 
2.292689398965 of 5 stars

Cerus scored higher than 46% of companies evaluated by MarketBeat, and ranked 295th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cerus has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Cerus has a consensus price target of $5.25, representing about 161.8% upside from its current price of $2.01.

  • Amount of Analyst Coverage

    Cerus has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cerus' stock forecast and price target.
  • Earnings Growth

    Earnings for Cerus are expected to grow in the coming year, from ($0.02) to $0.01 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cerus is -66.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cerus is -66.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cerus has a P/B Ratio of 5.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.65% of the float of Cerus has been sold short.
  • Short Interest Ratio / Days to Cover

    Cerus has a short interest ratio ("days to cover") of 8.18.
  • Change versus previous month

    Short interest in Cerus has recently decreased by 12.01%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cerus does not currently pay a dividend.

  • Dividend Growth

    Cerus does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cerus this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for CERS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Cerus to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cerus insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.30% of the stock of Cerus is held by insiders.

  • Percentage Held by Institutions

    78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cerus' insider trading history.
Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CERS Stock News Headlines

Wall Street Zen Upgrades Cerus (NASDAQ:CERS) to Buy
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Cerus (CERS) Q3 2026 Earnings Call Transcript
Cerus Corporation (CERS) Q3 2026 Earnings Call Transcript
See More Headlines

CERS Stock Analysis - Frequently Asked Questions

Cerus' stock was trading at $2.06 at the beginning of the year. Since then, CERS stock has decreased by 2.7% and is now trading at $2.0050.

Cerus Corporation (NASDAQ:CERS) released its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.00. The biotechnology company earned $63.30 million during the quarter, compared to analysts' expectations of $62.90 million. Cerus had a negative net margin of 3.23% and a negative trailing twelve-month return on equity of 10.44%.
Read the conference call transcript
.

Cerus' top institutional shareholders include State Street Corp (2.52%), Sumitomo Mitsui Trust Group Inc. (2.23%), Goldman Sachs Group Inc. (1.26%) and Ieq Capital LLC (1.24%). Insiders that own company stock include William Mariner Greenman, Vivek K Jayaraman, Kevin Dennis Green, Chrystal Jensen, Richard J Benjamin, Carol Moore, Eric Bjerkholt, Daniel N Swisher Jr and Hua Shan.
View institutional ownership trends
.

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cerus investors own include Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA), OPKO Health (OPK), Alibaba Group (BABA), Bristol Myers Squibb (BMY) and Nokia (NOK).

Company Calendar

Last Earnings
7/30/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Supplies
Current Symbol
NASDAQ:CERS
CIK
1020214
Employees
345
Year Founded
1991

Price Target and Rating

High Price Target
$6.50
Low Price Target
$4.00
Potential Upside/Downside
+163.2%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
199.50
P/E Growth
N/A
Net Income
-$15.63 million
Net Margins
-3.23%
Pretax Margin
-3.10%
Return on Equity
-10.44%
Return on Assets
-3.42%

Debt

Debt-to-Equity Ratio
0.46
Current Ratio
1.96
Quick Ratio
1.15

Sales & Book Value

Annual Sales
$206.13 million
Price / Sales
1.95
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.38 per share
Price / Book
5.25

Miscellaneous

Outstanding Shares
201,950,000
Free Float
191,250,000
Market Cap
$402.89 million
Optionable
Optionable
Beta
1.84

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:CERS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners